FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386009764> ?p ?o ?g. }

• W4386009764 endingPage "e54499e3" @default.
• W4386009764 startingPage "e54499e3" @default.
• W4386009764 abstract "Background: Brexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved in the US for adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) and in the EU for adults ≥26 years of age with R/R B-ALL based on positive results of ZUMA-3. After 3 years of follow-up in ZUMA-3, brexu-cel demonstrated an overall complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate of 71% and a median overall survival (OS) of 26.0 months in all treated patients (N=55) and 38.9 months in patients with CR (n=31; Shah et al. EU CAR T 2023. Abstract 34). Aims: Here, we report 3-year outcomes by age, number of prior therapies, prior blinatumomab, and subsequent allogeneic stem cell transplant (alloSCT). Methods: Patients (≥18 y) had R/R B-ALL and received a single brexu-cel infusion (1×10⁶ CAR T cells/kg) following leukapheresis and conditioning chemotherapy. The primary endpoint was overall CR/CRi rate per independent review. Post hoc subgroup analyses were exploratory, with descriptive statistics reported. Results: As of July 23, 2022, the median follow-up in Phase 2 (N=55) was 38.8 months (range, 32.7-44.6). The CR/CRi rate (95% CI) was 67% (35-90) for patients <26 years (n=12) and 72% (56-85) for patients ≥26 years (n=43). The median (95% CI) OS was 28.6 months (0.6-not estimable [NE]) for patients <26 years and 34.1 months (15.9-NE) for patients ≥26 years. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 92% of patients <26 years and in 88% of patients ≥26 years. For patients with 1 prior therapy (n=10), the CR/CRi rate was 90% (95% CI, 55-100) and for patients with ≥2 prior therapies (n=45), the CR/CRi rate was 67% (95% CI, 51-80); medians (95% CI) for OS were not reached (NR; 2.1-NE) and 25.6 months (14.2-38.9), respectively. The incidence of Grade ≥3 TRAEs was 90% for patients with 1 prior therapy and 89% for patients with ≥2 prior therapies. The CR/CRi rates (95% CI) for patients with (n=25) and without (n=30) prior blinatumomab were 60% (39-79) and 80% (61-92). The median (95% CI) OS was 14.2 months (3.2-26.0) for patients with prior blinatumomab and NR (18.6-NE) for patients without prior blinatumomab; Grade ≥3 TRAEs occurred in 80% and 97% of patients, respectively. For responders (CR/CRi) who did (n=10) or did not (n=29) proceed to subsequent alloSCT, the median (95% CI) OS was NR (7.6-NE) and 38.9 months (18.6-NE), respectively. Similar efficacy results were observed in a pooled subgroup analysis of Phase 1 and 2 patients treated at the pivotal dose (N=78), with a median follow-up of 41.6 months (range, 32.7-70.3). Summary/Conclusion: Adults with R/R B-ALL benefitted from brexu-cel, regardless of age, number of prior therapies, prior blinatumomab exposure, or subsequent alloSCT status. Survival appeared longer in patients with fewer prior therapies and in blinatumomab-naïve patients; however, small patient numbers and unmatched baseline characteristics limit interpretation of these results. Additional studies are needed to determine the impact of prior therapies and/or subsequent alloSCT on outcomes of patients who receive brexu-cel. Keywords: Hematopoietic cell transplantation, Relapsed acute lymphoblastic leukemia, CAR-T, CD19" @default.
• W4386009764 created "2023-08-21" @default.
• W4386009764 creator A5013177563 @default.
• W4386009764 creator A5017200652 @default.
• W4386009764 creator A5021579716 @default.
• W4386009764 creator A5022937583 @default.
• W4386009764 creator A5025137989 @default.
• W4386009764 creator A5029533472 @default.
• W4386009764 creator A5031216970 @default.
• W4386009764 creator A5037299848 @default.
• W4386009764 creator A5039996784 @default.
• W4386009764 creator A5040504519 @default.
• W4386009764 creator A5049413660 @default.
• W4386009764 creator A5049910941 @default.
• W4386009764 creator A5056999581 @default.
• W4386009764 creator A5064294460 @default.
• W4386009764 creator A5071733656 @default.
• W4386009764 creator A5071844603 @default.
• W4386009764 creator A5076973611 @default.
• W4386009764 creator A5085514831 @default.
• W4386009764 creator A5089893290 @default.
• W4386009764 creator A5091739351 @default.
• W4386009764 date "2023-08-01" @default.
• W4386009764 modified "2023-10-16" @default.
• W4386009764 title "P367: LONG-TERM OUTCOMES OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH BREXUCABTAGENE AUTOLEUCEL IN ZUMA-3 BY AGE, PRIOR THERAPIES, AND SUBSEQUENT TRANSPLANT" @default.
• W4386009764 doi "https://doi.org/10.1097/01.hs9.0000968380.54499.e3" @default.
• W4386009764 hasPublicationYear "2023" @default.
• W4386009764 type Work @default.
• W4386009764 citedByCount "0" @default.
• W4386009764 crossrefType "journal-article" @default.
• W4386009764 hasAuthorship W4386009764A5013177563 @default.
• W4386009764 hasAuthorship W4386009764A5017200652 @default.
• W4386009764 hasAuthorship W4386009764A5021579716 @default.
• W4386009764 hasAuthorship W4386009764A5022937583 @default.
• W4386009764 hasAuthorship W4386009764A5025137989 @default.
• W4386009764 hasAuthorship W4386009764A5029533472 @default.
• W4386009764 hasAuthorship W4386009764A5031216970 @default.
• W4386009764 hasAuthorship W4386009764A5037299848 @default.
• W4386009764 hasAuthorship W4386009764A5039996784 @default.
• W4386009764 hasAuthorship W4386009764A5040504519 @default.
• W4386009764 hasAuthorship W4386009764A5049413660 @default.
• W4386009764 hasAuthorship W4386009764A5049910941 @default.
• W4386009764 hasAuthorship W4386009764A5056999581 @default.
• W4386009764 hasAuthorship W4386009764A5064294460 @default.
• W4386009764 hasAuthorship W4386009764A5071733656 @default.
• W4386009764 hasAuthorship W4386009764A5071844603 @default.
• W4386009764 hasAuthorship W4386009764A5076973611 @default.
• W4386009764 hasAuthorship W4386009764A5085514831 @default.
• W4386009764 hasAuthorship W4386009764A5089893290 @default.
• W4386009764 hasAuthorship W4386009764A5091739351 @default.
• W4386009764 hasBestOaLocation W43860097641 @default.
• W4386009764 hasConcept C121332964 @default.
• W4386009764 hasConcept C126322002 @default.
• W4386009764 hasConcept C141071460 @default.
• W4386009764 hasConcept C142424586 @default.
• W4386009764 hasConcept C187212893 @default.
• W4386009764 hasConcept C2778020697 @default.
• W4386009764 hasConcept C2778461978 @default.
• W4386009764 hasConcept C2909962599 @default.
• W4386009764 hasConcept C71924100 @default.
• W4386009764 hasConcept C87355193 @default.
• W4386009764 hasConcept C90924648 @default.
• W4386009764 hasConceptScore W4386009764C121332964 @default.
• W4386009764 hasConceptScore W4386009764C126322002 @default.
• W4386009764 hasConceptScore W4386009764C141071460 @default.
• W4386009764 hasConceptScore W4386009764C142424586 @default.
• W4386009764 hasConceptScore W4386009764C187212893 @default.
• W4386009764 hasConceptScore W4386009764C2778020697 @default.
• W4386009764 hasConceptScore W4386009764C2778461978 @default.
• W4386009764 hasConceptScore W4386009764C2909962599 @default.
• W4386009764 hasConceptScore W4386009764C71924100 @default.
• W4386009764 hasConceptScore W4386009764C87355193 @default.
• W4386009764 hasConceptScore W4386009764C90924648 @default.
• W4386009764 hasIssue "S3" @default.
• W4386009764 hasLocation W43860097641 @default.
• W4386009764 hasOpenAccess W4386009764 @default.
• W4386009764 hasPrimaryLocation W43860097641 @default.
• W4386009764 hasRelatedWork W2003938723 @default.
• W4386009764 hasRelatedWork W2047967234 @default.
• W4386009764 hasRelatedWork W2118496982 @default.
• W4386009764 hasRelatedWork W2351796763 @default.
• W4386009764 hasRelatedWork W2364998975 @default.
• W4386009764 hasRelatedWork W2369162477 @default.
• W4386009764 hasRelatedWork W2439875401 @default.
• W4386009764 hasRelatedWork W2567738959 @default.
• W4386009764 hasRelatedWork W4238867864 @default.
• W4386009764 hasRelatedWork W2525756941 @default.
• W4386009764 hasVolume "7" @default.
• W4386009764 isParatext "false" @default.
• W4386009764 isRetracted "false" @default.
• W4386009764 workType "article" @default.